Mr. To has been a Director since 2000 and an Executive Director and chairman of the Board since 2006. He is also Chairman of our nomination committee, a member of the remuneration committee and technical committee. He is the managing director of Hutchison Whampoa (China) Limited and has been with Hutchison Whampoa (China) Limited for over 38 years, building its business from a small trading company to a multi-billion dollar investment group. He has negotiated major transactions with multinational corporations such as Procter & Gamble, or P&G, Lockheed, Pirelli, Beiersdorf, United Airlines, and British Airways. He is currently the chairman of Gama Aviation Plc, which is admitted to trading on AIM (stock code: GMAA) and formerly served as an independent non-executive director on the boards of China Southern Airlines Company Limited and Air China Limited.
Mr. To’s career in China spans more than 43 years. He is the original founder of China healthcare business of Hutchison Whampoa Limited (currently a subsidiary of CK Hutchison Holdings Limited (“CKHH”)) and has been instrumental in the acquisitions made to date. He received a Bachelor’s Degree in Mechanical Engineering from Imperial College, London in 1973 and an MBA from Stanford University’s Graduate School of Business in 1975.
Mr. Hogg has been an Executive Director and our chief executive officer since 2006. He is also a member of our nomination committee and technical committee. He joined the business in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of our strategy, business and listings. This includes the establishment of our Innovation Platform, Hutchison MediPharma, which now comprises 8 drug candidates that are being investigated in clinical studies around the world and a scientific team of about 440 people based in Shanghai. Furthermore, Mr. Hogg oversaw the acquisition and operational integration of assets that led to the formation of our Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Prior to joining us, Mr. Hogg spent ten years with P&G, starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. He then moved to China to manage P&G’s detergent business, followed by a move to Brussels to run P&G’s global bleach business.
Mr. Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh in 1987 and an MBA from the University of Tennessee in 1989.
Mr. Cheng has been an Executive Director since 2011 and our Chief Financial Officer since 2008. He is also a member of our nomination committee.
Prior to joining our Company, Mr. Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia in 1989. In 1995, he joined KPMG in Beijing before spending eight years with Nestlé in China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a Bachelor of Economics from the University of Adelaide in 1988 and has been a member of the Chartered Accountants Australia and New Zealand since 1992.
Dr. Su has been an Executive Director of the Company since 2017 and has been our chief scientific officer since 2012. He is also a member of our nomination committee and technical committee. Dr. Su has headed all drug discovery and research since he joined our company, including master-minding the Company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in our pipeline. Prior to joining the Group in 2005, Dr. Su worked with Pfizer's U.S. research and development organization.
In 2017, he was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai in 1982 and completed a Ph.D. and Post-Doctoral Fellowship in Chemistry at Harvard University in 1988 under the guidance of Nobel Laureate Professor E. J. Corey.
Dr. Eldar (formerly Perlmutter) has been a Non-executive Director since 2016. He is also a member of our nomination committee. He has more than 30 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare. He is an executive director of Hutchison Water Israel Ltd (an associated company of CKHH), which focuses on large scale projects including desalination, wastewater treatment and water reuse. He was formerly an independent non-executive director of Leumi Card Ltd., a subsidiary of Bank Leumi Le-Israel B.M., one of Israel’s leading credit card companies.
Dr. Eldar received a Doctor of Philosophy degree in Government from Harvard University in 1983, a Master of Arts degree in Government from Harvard University in 1982, Master of Arts degree in Political Science and Public Administration from the Hebrew University of Jerusalem in 1980 and a Bachelor of Arts degree in Political Science from the Hebrew University of Jerusalem in 1977.
Ms. Shih has been a Non-executive Director since 2006, the company secretary since 2000 and the company secretary of Group companies since 2000. She is also a member of our nomination committee. She is an executive director and the company secretary of CKHH. She has been with the Cheung Kong (Holdings) Limited ("CKH") group since 1989 and from 1991 to 2015 with Hutchison Whampoa Limited ("HWL") both of which have become wholly-owned subsidiaries of CKHH in 2015. She has acted in various capacities within the CKHH, CKH, HWL groups including director, head group general counsel and company secretary of HWL and its subsidiaries and associated companies. Ms. Shih is a non-executive director of Hutchison Telecommunications Hong Kong Holdings Limited which is listed on the Hong Kong Stock Exchange (stock code: 00215) and Hutchison Port Holdings Management Pte. Limited, the trustee-manager of Hutchison Port Holdings Trust which is listed on the Singapore Stock Exchange (stock code: NS8U). She is also a member of the board of commissioners of PT Duta Intidaya Tbk, which is listed on Jakarta Stock Exchange (stock code: DAYA). She has over 35 years of experience in legal, regulatory, corporate finance, compliance and corporate governance fields. She is at present the international president and executive committee chairman of the Institute of Chartered Secretaries and Administrators and a past president and current chairperson or member of certain working groups and panels of The Hong Kong Institute of Chartered Secretaries. Ms. Shih received a Bachelor of Science degree in Education in 1973 and a Master of Arts degree in 1975 from the University of the Philippines and a Master of Arts degree in 1977 and a Master of Education degree in 1978 from Columbia University, New York. She qualifies as a solicitor in England and Wales, Hong Kong and Victoria, Australia in 1984 and has been a Fellow of both the Institute of Chartered Secretaries and Administrators and The Hong Kong Institute of Chartered Secretaries since 2004, with Chartered Secretary and Chartered Governance Professional dual designations.
Mr. Carter has been a senior Independent Non-executive Director since 2017. He is also the chairman of our remuneration committee and a member of our audit committee, nomination committee and technical committee. He has more than 25 years of experience in the pharmaceutical industry having previously worked at Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company, with the last position as executive vice president, commercial operations. In this role, Mr. Carter headed the worldwide commercial organisation responsible for the launch and commercialisation of all of Gilead’s products. He also worked as a senior executive at GlaxoSmithKline Plc. He is currently a director of Alder Biopharmaceuticals, Inc, which is listed on NASDAQ Global Market (stock code: ALDR) and Mallinckrodt Plc, which is listed on the New York Stock Exchange (stock code: MNK). Mr. Carter received a degree in Business Studies from the Ealing School of Business and Management (now merged into the University of West London) in 1983 and has been a Fellow of the Chartered Institute of Management Accountants in the United Kingdom since 1991.
Dr. Ferrante has been an Independent Non-executive Director since 2017. She is also the chairman of our technical committee and a member of our audit committee and nomination committee. She has more than 20 years of experience in the pharmaceutical industry. She was the former chief medical officer and head of research and development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercialising innovative therapies for prostate cancer and other hormonally driven diseases. In 2014, Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including chief medical officer and most recently as oncology therapeutic area and Cambridge USA site head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Inc., with the last position as vice president, oncology development. Dr. Ferrante is currently a member of the board of directors of Progenics Pharmaceuticals, Inc., which is listed on NASDAQ (stock code: PGNX), MacroGenics, Inc., which is listed on NASDAQ (stock code: MGNX) and Unum Therapeutics Inc., which is listed on NASDAQ (stock code: UMRX). She was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016. She is an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr. Ferrante received a Bachelor of Science Degree in Chemistry and Biology from Providence College in 1980 and a Doctor of Medicine from Georgetown University in 1988.
Mr. Jack has been an Independent Non-executive Director since 2017. He is also chairman of our audit committee and member of our remuneration committee and nomination committee. He has more than 40 years of experience in finance and audit. He retired as partner of PricewaterhouseCoopers in 2006 after a distinguished career with the firm for over 33 years. He is currently an independent non-executive director of The Greenbrier Companies, Inc. (an international supplier of equipment and services to the freight rail transportation markets, which is listed on the New York Stock Exchange (stock code: GBX)), Hutchison Port Holdings Management Pte. Limited as the trustee-manager of Hutchison Port Holdings Trust (a developer and operator of deep water container terminals, which is listed on the Singapore Stock Exchange (stock code: NS8U)) and of COSCO SHIPPING Development Co., Ltd. (stock code: 2866), formerly known as “China Shipping Container Lines Company Limited” (an integrated financial services platform principally engaged in vessel and container leasing).
He received a Bachelor of Commerce degree from the University of New South Wales, Australia in 1973 and has been a Fellow of the Hong Kong Institute of Certified Public Accountants since 1987 and an Associate of Chartered Accountants Australia and New Zealand since 1976.
Professor Mok has been an Independent Non-executive Director since 2017. He is also a member of our nomination committee and technical committee. Professor Mok has more than 30 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer. He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong. Professor Mok has contributed to over 200 articles in international peer-reviewed journals, as well as multiple editorials and textbooks. In 2018, Professor Mok was the first Chinese to be bestowed with the European Society of Clinical Oncology (ESMO) Lifetime Achievement Award, one of the most prestigious international honours and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide. He is an independent non-executive director of AstraZeneca Plc, which is listed on the main market of the London Stock Exchange (stock code: AZN), a director of the American Society of Clinical Oncology (ASCO), a member of the ASCO Publications Committee and vice chairman of the Chinese Society of Clinical Oncology (CSCO). He also formerly chaired the ASCO International Affairs Committee. Professor Mok is closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People's Hospital and Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He received his Bachelor of Medical Science degree in 1982 and a Doctor of Medicine from University of Alberta, Canada. He has also been a Fellow of the Royal College of Physicians and Surgeons of Canada since 1988, Hong Kong College of Physicians since 1996, Hong Kong Academy of Medicine since 1997, Royal College of Physicians of Edinburgh since 2014 and ASCO since 1996.